Colleyville, TX, August 16, 2009 --(PR.com
)-- Heart Test Laboratories Inc. (HTL), is a rapidly developing medical technology company concentrating on inventing life saving devices for the Coronary Arterial Disease (CAD) market. Heart Test Laboratories is in the final stages of releasing it's new patent pending screening device, the MyoVista™, which can detect Myocardial Ischemia in 90 seconds or less. MyoVista is a portable, inexpensive, diagnostic device used to determine the presence and level of Myocardial Ischemia, a restriction of blood flow to the heart, which is a contributing factor in 67% of all Coronary Arterial Disease.
"Our latest expansion allows us more opportunities for growth", says Diaz. "By enhancing our infrastructure, we are better equipped to further develop our products and programs, as well as support our physicians, hospitals, and clinics utilizing the MyoVista Myocardial Ischemia screening device."
With five years of testing along with the current Heart Test Labs clinical trials, MyoVista has shown an average 90% or better correlation to an invasive angiogram.